Discovery & Development

For inhaler technology to evolve, questions about efficacy must be answered.

Why your efforts to introduce "PAT" may not be working as intended…

Publishing negative results might not flatter – but it does matter.

How do we fix the course of pediatric medicine to ensure the best treatments for children of all ages?

Sitting Down With… Tony van Bijleveld, BU Head of Softgels, Pharma Services Group, Thermo Fisher Scientific, the Netherlands.

How a better understanding of raw materials has increased the potential for biopharmaceutical companies to understand their process variability.

New cancer treatments may be lying right under our noses – if we are willing to take a commercial risk.

Outsourcing partnerships aim to reduce costs and improve efficiencies, but don't overlook the human elements!

Some patients, particularly children, find medicines unpalatable – and genetics could be the cause.

Industry gurus Frank Romanski, Derek Bush and Kishor Wasan share their views and tips for formulation success.